Form 4: Zenas BioPharma Director Xiao Ting Acquires 37,000 Stock Options

Director Xiao Ting acquired 37,000 stock options in Zenas BioPharma, Inc. on September 12, 2024, according to a Form 4 filing.

Summary

• On September 12, 2024, Xiao Ting, a director of Zenas BioPharma, Inc. (ZBIO), acquired 37,000 stock options.
• The options have an exercise price of $17.
• The options vest in equal annual installments over three years, starting on September 12, 2025, subject to continued service.
• The options expire on September 11, 2034.
• Following the transaction, Xiao Ting directly owns 37,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director can be seen as a sign of confidence in the company, but it's a routine transaction.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) trade in their company's stock. This filing indicates a transaction by a director of Zenas BioPharma.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates